In 2008, new Food and Drug Administration (FDA) requirements curtailed the marketing of pancreatic enzyme products (PEPs) by establishing new quality standards for their use in the United States; this revision comes at a price. Th e outcome raises issues about optimal means of retroactively regulating widely used products predating the FDA.
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In 1938, the Food, Drug, and Cosmetic Act mandated that new drugs undergo a formal review process to ensure drug quality and standardization; as PEPs were not new, they were not subject to the approval process ( 1 ) . PEPs are complex, porcine-derived medications containing mixtures of lipases, proteases, and amylases. Th ey are used to treat symptoms of exocrine pancreatic insuffi ciency resulting from cystic fi brosis, total or partial pancreatectomy, and chronic pancreatitis ( 2 ) . In the early 2000s, prompted by reported product interchange failures, a rise in over-the counter PEPs that were not generally recognized as safe and eff ective, and pressure from patient advocacy groups, the FDA reviewed PEPs and found wide quality variability ( 3, 4 ) . As a result, the FDA mandated that PEPs undergo a formal new drug application (NDA) process. A guide issued in 2006 described the safety, effi cacy, and quality requirements that PEP manufacturers would have to meet for approval by 2009 ( 2 ) .
Before the NDA requirement, there were ~ 25 diff erent prescription enzyme formulations available with varying dosages of lipase, protease, and amylase. However, because the FDA approval process required the conduct of prospective clinical trials to ensure manufacturing standardization and clinical eff ectiveness, most manufacturers opted not to pursue approval ( 1 ) . In May 2013, there were only six FDA-approved PEPs ( 2 ) .
Given the expense of conducting the prospective clinical trials and marketing new formulations, in the context of reduced market competition, we hypothesized that an unintended consequence of FDA regulation may have been an increase in prescription costs and a decrease in patient prescription access. We used IMS Health data (Danbury, CT) to calculate the annual total number of prescriptions and sales (US Dollars) for PEPs ( 5 ). Th e IMS Health Product Report 5.0 database tracks pharmaceutical sales records in the United States and is a leading source of economic indicators for the pharmaceutical industry. We studied years 2008 through 2012, a timeframe encompassing the FDA action and industry response. Th e cost per prescription was calculated by dividing total prescriptions by total annual sales.
Since 2008, total PEP prescriptions and the cost per PEP prescription have risen ( Figure 1 ). In 2008, PEP sales from prescriptions totaled $ 282 million; by 2012, this had increased to $ 675 million (up 240 % ), whereas total prescription volume changed little. With dramatically increased costs per prescription and decreased market competition, did the NDA requirement satisfy the goal of patient advocacy groups in " making enzymes better? " ( 6 ) From the perspective of the FDA, PEP clinical effi cacy has been proven and individual products standardized. From the manufacturer ' s perspective, the NDA process was either a boon or a loss. Manufacturers that conducted trials have benefi ted fi nancially because of the universal prescription price increases.
From the individual patient perspective, it is diffi cult to quantify the eff ect of this FDA regulation. Certainly, having access to consistent and eff ective PEP formulations should be beneficial and evoke confi dence in the products. However, the clinical effi cacy studies upon which the approvals were based were of short duration and had small numbers of participants; each evaluated just one PEP formulation ( 1 ) . Because the FDA did not require studies of comparative effi cacy between formulations, the NDA process did not directly answer the principal motivating question of PEP therapeutic interchangeability; the individual patient is likely no closer to determining the most eff ective PEP, and is now paying twice the previous price for each PEP prescription. Based on national prescription volume, we see no change in the total annual prescriptions fi lls over this timeframe, suggesting access was not aff ected -see Figure 1 . However, a price-induced shift to smaller dispensings (e.g., a shift from 90-day supply to 30-day supply) would not be noted in this simple count of fi lls and seems probable for uninsured and underinsured patients.
Was the NDA PEP approval process worthwhile? Unfortunately, the answer is not clear. Although measuring the direct economic
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Timothy B. Gardner , MD, MS 1 impact of this regulatory action is relatively straightforward, there is no simple method to assess the impact of this action on quality and length of life for PEP users. Without such an evaluation, we cannot know the value of the NDA requirement from the patient or societal perspective. If the safeguards such as patient assistance programs prove insuffi cient, it seems certain a substantial number of patients will reduce their use of PEPs in response to the increased fi nancial barriers. For some, this " cost " may seem acceptable in exchange for predictable products; others will disagree, especially those negatively aff ected.
Could we have found another path to standardization and quality assurance? Th erapeutic interchangeability may have been established without time and cost-intensive prospective randomized trials. Quality and uniformity tests of individual formulations might have been suffi cient. By subjecting each product to rigorous content and uniformity analysis, the purity and consistency of each individual PEP may have been determined. Th e ability of physiochemical and biological analytical tools to demonstrate similarity between active ingredients from two diff erent manufacturers is limited, but individual product testing likely would have suffi ced to assure consistency and purity ( 2 ). Enzyme products not meeting preestablished quality standards could then have been required to complete clinical trials.
As long-term outcomes studies are unlikely to be conducted, we may never have full accounting of the value of this interventionthe balance of benefi t and cost. Th ere is precedent for compromising aff ordability for known effi cacy of drugs long viewed as safe and eff ective, but that does not mean that such decisions should be repeated ( 7 ) . As the nation continues to wrestle with recognition of fi nite health-care dollars, such tradeoff s deserve careful consideration. Alternative approaches that balance industry incentive and national interest must be pursued. 
